Logo

SeqWright to Handle DNA Screening/Genotyping for Third Wave's HPV Trials

Jan 04, 2007
NEW YORK (GenomeWeb News) — SeqWright today said it will perform all of the sequencing and analysis for a set of clinical trials being conducted by Third Wave Technologies.
 
Third Wave is developing two in vitro molecular assays and a genotyping test to screen for human papillomavirus, which has been identified as the cause of approximately 70 percent of cervical cancer cases, SeqWright said.
 
Third Wave’s tests will detect and identify 14 HPV high-risk types and HPV types 16 and 18, the company said.   
 
SeqWright uses gene sequencing and bioinformatics technologies to help companies run clinical trials for FDA submission.

Filed under

Clinical Sequencing
Sequencing
Informatics
Breaking News
The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.